Literature DB >> 18541685

Risk factors for ovarian hyperstimulation syndrome in Thai patients using gonadotropins for in vitro fertilization.

Pornanong Aramwit1, Kamthorn Pruksananonda, Narat Kasettratat, Karnphat Jammeechai.   

Abstract

PURPOSE: A prospective observational study was conducted to identify risk factors for ovarian hyperstimulation syndrome (OHSS) in Thai patients using gonadotropins for in vitro fertilization.
METHODS: Outpatients receiving a short and a long protocol of ovarian stimulation with a recombinant follicle-stimulating hormone (rec FSH) at a Bangkok hospital were enrolled. Patients in the short protocol received rec FSH and the gonadotropin-releasing-hormone agonist buserelin acetate by subcutaneous injection after blood sampling on day 2 of the patient's cycle. When one or more follicles reached a diameter of 18 mm as determined by ultrasonography and the serum estradiol (E(2)) concentration exceeded 400 pg/mL, patients received human chorionic gonadotropin (hCG); oocytes were retrieved 34-36 hours later. The long protocol differed only in that patients received nasal buserelin acetate and rec FSH 10 days before the cycle started and on day 2 of the cycle. Serum levels of E(2), luteinizing hormone, and FSH were monitored at baseline. In addition to E(2) concentration and follicle size and number, patients' weight, waist circumference, complete blood counts, and C-reactive protein (CRP) levels were monitored at intervals. Patients were instructed to notify the hospital of any symptoms of OHSS.
RESULTS: Of 117 patients enrolled, 13 had moderate OHSS and 1 had severe OHSS; all recovered. Patients with OHSS were significantly younger, had significantly lower body mass index, and had significantly higher E(2) before hCG injection, total number of follicles, total number of oocytes retrieved, and white blood cell and neutrophil counts after hCG injection. Patients with polycystic ovary syndrome were significantly more likely to have OHSS. CRP levels were higher in OHSS patients, but the difference was not significant. Multiple logistic regression showed that the combination of serum E(2) peak concentration of > or =4500 pg/mL and total number of oocytes retrieved of > or =15 predicted the occurrence of moderate-to-severe OHSS; 12 of 14 study patients who met these criteria had OHSS.
CONCLUSION: Serum E(2) peak concentrations of > or =4500 pg/mL and total number of oocytes > or =15 may be useful indicators for identifying patients at high risk for moderate-to-severe OHSS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18541685     DOI: 10.2146/ajhp070566

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  8 in total

1.  What is the best predictor of severe ovarian hyperstimulation syndrome in IVF? A cohort study.

Authors:  Theoni B Tarlatzi; Christos A Venetis; Fabienne Devreker; Yvon Englert; Anne Delbaere
Journal:  J Assist Reprod Genet       Date:  2017-07-14       Impact factor: 3.412

2.  The impact of polycystic ovary syndrome and body mass index on the absorption of recombinant human follicle stimulating hormone.

Authors:  Malinda S Lee; Andrea Lanes; Andrey V Dolinko; Alexandra Bailin; Elizabeth Ginsburg
Journal:  J Assist Reprod Genet       Date:  2020-07-04       Impact factor: 3.412

Review 3.  Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis.

Authors:  Héctor F Escobar-Morreale; Manuel Luque-Ramírez; Frank González
Journal:  Fertil Steril       Date:  2010-12-17       Impact factor: 7.329

4.  Optimal cutoff value of basal anti-mullerian hormone in iranian infertile women for prediction of ovarian hyper-stimulation syndrome and poor response to stimulation.

Authors:  Malek Mansour Aghssa; Azam Manshadi Tarafdari; Ensieh Shahrokh Tehraninejad; Mohammad Ezzati; Maryam Bagheri; Zahra Panahi; Saeed Mahdavi; Mehrshad Abbasi
Journal:  Reprod Health       Date:  2015-09-10       Impact factor: 3.223

5.  Artificial colloids versus human albumin for the treatment of ovarian hyperstimulation syndrome: A retrospective cohort study.

Authors:  Tetsuji Minami; Hayato Yamana; Mph Ph D; Daisuke Shigemi; Hiroki Matsui Mph; Kiyohide Fushimi; Hideo Yasunaga
Journal:  Int J Reprod Biomed       Date:  2019-11-07

6.  Factors Associated with Ovarian Hyperstimulation Syndrome (OHSS) Severity in Women With Polycystic Ovary Syndrome Undergoing IVF/ICSI.

Authors:  Bo Sun; Yujia Ma; Lu Li; Linli Hu; Fang Wang; Yile Zhang; Shanjun Dai; Yingpu Sun
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-19       Impact factor: 5.555

7.  A comparative, observational study evaluating dosing characteristics and ovarian response using the recombinant human follicle-stimulating hormone pen injector with small-dose dial in assisted reproductive technologies treatment in Asia: IMPROVE study.

Authors:  Bum Chae Choi; Canquan Zhou; Hong Ye; Yun Sun; Ying Zhong; Fei Gong; Ivan Sini; Nadezda Abramova; Salvatore Longobardi; Miranda Hickey; Thomas D'Hooghe
Journal:  Reprod Biol Endocrinol       Date:  2022-01-17       Impact factor: 5.211

8.  The influence of obesity on incidence of complications in patients hospitalized with ovarian hyperstimulation syndrome.

Authors:  Rachel S Mandelbaum; Liat Bainvoll; Caroline J Violette; Meghan B Smith; Shinya Matsuzaki; Maximilian Klar; Jacqueline R Ho; Kristin A Bendikson; Richard J Paulson; Koji Matsuo
Journal:  Arch Gynecol Obstet       Date:  2021-07-09       Impact factor: 2.344

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.